202 related articles for article (PubMed ID: 6956429)
1. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma.
Ettinger LJ; Chervinsky DS; Freeman AI; Creaven PJ
Cancer; 1982 Nov; 50(9):1676-82. PubMed ID: 6956429
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis.
Tetef ML; Margolin KA; Doroshow JH; Akman S; Leong LA; Morgan RJ; Raschko JW; Slatkin N; Somlo G; Longmate JA; Carroll MI; Newman EM
Cancer Chemother Pharmacol; 2000; 46(1):19-26. PubMed ID: 10912573
[TBL] [Abstract][Full Text] [Related]
3. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
4. High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group pilot study.
Frankel LS; Wang YM; Shuster J; Nitschke R; Doering EJ; Pullen J
J Clin Oncol; 1983 Dec; 1(12):804-9. PubMed ID: 6583318
[TBL] [Abstract][Full Text] [Related]
5. High-dose methotrexate in acute lymphocytic leukemia.
Freeman AI; Wang JJ; Sinks LF
Cancer Treat Rep; 1977 Jul; 61(4):727-31. PubMed ID: 267510
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics of intrathecal chemotherapy and clinical problems].
Fujimoto T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1536-42. PubMed ID: 6433796
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.
Millot F; Rubie H; Mazingue F; Mechinaud F; Thyss A
Leuk Lymphoma; 1994 Jun; 14(1-2):141-4. PubMed ID: 7920221
[TBL] [Abstract][Full Text] [Related]
8. Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia.
Evans WE; Stewart CF; Hutson PR; Cairnes DA; Bowman WP; Yee GC; Crom WR
Drug Intell Clin Pharm; 1982 Nov; 16(11):839-42. PubMed ID: 6959800
[TBL] [Abstract][Full Text] [Related]
9. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya methotrexate administration in patients with meningeal carcinomatosis.
Mehta BM; Glass JP; Shapiro WR
Cancer Res; 1983 Jan; 43(1):435-8. PubMed ID: 6600162
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
11. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Morra E; Lazzarino M; Inverardi D; Brusamolino E; Orlandi E; Canevari A; Pagnucco G; Bernasconi C
J Clin Oncol; 1986 Aug; 4(8):1207-11. PubMed ID: 3461134
[TBL] [Abstract][Full Text] [Related]
12. Remission induction of meningeal leukemia with high-dose intravenous methotrexate.
Balis FM; Savitch JL; Bleyer WA; Reaman GH; Poplack DG
J Clin Oncol; 1985 Apr; 3(4):485-9. PubMed ID: 3856631
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma.
Vassal G; Valteau D; Bonnay M; Patte C; Aubier F; Lemerle J
Pediatr Hematol Oncol; 1990; 7(1):71-7. PubMed ID: 2397170
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
15. Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing.
Strother DR; Glynn-Barnhart A; Kovnar E; Gregory RE; Murphy SB
J Clin Oncol; 1989 Nov; 7(11):1741-7. PubMed ID: 2809687
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
17. Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5-33.6 g/m2 to children with acute lymphoblastic leukemia.
Borsi JD; Sagen E; Romslo I; Moe PJ
Med Pediatr Oncol; 1990; 18(3):217-24. PubMed ID: 2329967
[TBL] [Abstract][Full Text] [Related]
18. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.
Borsi JD; Moe PJ
Cancer; 1987 Jul; 60(1):5-13. PubMed ID: 3472638
[TBL] [Abstract][Full Text] [Related]
19. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
20. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
